Research progress in the economic burden of inflammatory bowel disease
10.3760/cma.j.cn101480-20220824-00134
- VernacularTitle:炎症性肠病经济负担的研究进展
- Author:
Zhangqin LI
1
;
Qi HUANG
1
;
Maojuan LI
1
;
Yinglei MIAO
1
Author Information
1. 昆明医科大学第一附属医院消化内科，昆明 650032
- Publication Type:Journal Article
- Keywords:
Inflammatory bowel disease;
Biologics;
Economic burden;
Health economics;
Influencing factors
- From:
Chinese Journal of Inflammatory Bowel Diseases
2023;07(3):286-291
- CountryChina
- Language:Chinese
-
Abstract:
Inflammatory bowel disease (IBD) has recurrent and protracted course with unknown etiology and it can affect multiple organs and systems. At present, IBD patients tends to be younger, and the recurrent disease affects work, even resulting in unemployment, and consumes a lot of social and medical resources. Having been used for the treatment of IBD for more than 20 years, biologics increase the selectivity of treatment, but at the same time, current research has found that the use of biologics is one of the main factors increasing the economic burden of IBD. Compared with biologics, biosimilars have significant advantages in optimizing cost-benefit and have good application prospects. By summarizing the current research status of IBD health economics at home and abroad, this review aims to provide an economic basis for strengthening disease management and improving the quality of life of patients.
